Kay Etzler, the program manager at the National Institutes of Health’s SBIR Commercialization Assistance Program (CAP), notified Xemed CEO Bill Hersman that Xemed has been selected to participate in this year’s program. Within that program, Xemed has been assigned to the Accelerator Commercialization Track (ACT), the track assigned to companies that are further along their commercialization pathway. Once again this year the program will be implemented by the Larta Institute, a professional services firm that designs and manages commercialization programs on behalf of clients such as the NIH. Over the next six months, Prof. Hersman will be meeting with Xemed’s assigned Principal Advisor, a selected Expert Resource, and Larta staff to identify and achieve customized goals that will advance Xemed’s SBIR-developed products and services towards commercialization.
Xemed selected to participate in the 2010-2011 NIH SBIR Commercialization Assistance Program
ABOUT XEMED—We are a product-focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gases, partnering with clinical researchers and the pharmaceutical industry to advance pulmonary functional MRI through regulatory approval towards worldwide commercial availability.
At Xemed, our mission is to develop inhaled diagnostic agents that are capable of improving the standard of care of respiratory diseases. We will accomplish this by establishing hyperpolarized gas as a scientifically robust, clinically validated, FDA approved, and publically available diagnostic agent for magnetic resonance imaging of lung functional microstructure. We work to demonstrate effectiveness in two fields: 1) guiding clinical management of respiratory diseases, and 2) as a drug development tool to evaluate of the safety and efficacy of new therapies